Google
ABP Stock Price & Analysis — Abpro Holdings, Inc. (Healthcare >> Biotechnology)
ABP FAQ
What is ABP's P/E ratio?
Abpro Holdings, Inc. (ABP) currently trades at a P/E ratio of 2.76.
What is ABP's ROE?
Abpro Holdings, Inc. reports a Return on Equity (ROE) of 32.75%.
What is ABP's dividend yield?
Abpro Holdings, Inc. offers a dividend yield of 0.00%.
What is ABP's Quality Score?
Our AI rates ABP's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy ABP?
Our AI Timing Score for ABP is 3 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does ABP belong to?
Abpro Holdings, Inc. is classified under the Healthcare >> Biotechnology sector on the NYSE exchange
ABP AI Analysis Summary
Our AI summary for ABP: Abpro Holdings, Inc. (NYSE), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 2.76, ROE of 32.75%, a dividend yield of 0.00%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 3/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 5.70
Price
0.00
(0.00%)
Day Change
|
|
|---|
ABP, the overall quality is not quite good ( Quality = 54) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROA is relatively low.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
54% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 5.70 |
| PBV / Sector |
-1.88 / 44,022.72
|
| Earning Per Share | -1.06 |
| PE / Sector |
2.76 / 19.17
GREAT
|
| PEG or PE/Growth / Sector |
-0.08 / 1.24
|
| Average 1M Daily Value |
0.02 M
GREAT
|
| Average 1W Daily Value |
0.01 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
37% |
| Ability to Make Profit |
|
52% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-05 07:59:46 |
| Symbol | ABP |
| Name | ABPRO HOLDINGS, INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NYSE |
| Listed Shares | 2.72 M |
| Par Value | N/A |
| Calculated From | YearEnd |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 15.58 / 9,586.08 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 68 Cummings Park Drive, Woburn, MA, United States, 01801
Phone: 800 396 5890
Website: https://abpro.co
Sector: Healthcare >> Biotechnology
Description: Abpro Holdings, Inc., a biotechnology company, focuses on novel antibody constructs for immuno-oncology and ophthalmology. Its platforms include DiversImmune, a discovery platform that generates a diverse collection of proprietary antibodies against clinically validated and novel targets; and MultiMab, an engineering platform that provides the flexibility to combine antibody building blocks in different combinations and orientations to create fit for purpose novel full-length multi-specific antibody constructs. The company's lead product candidates include ABP-102, a next generation immuno-oncology TetraBi antibody targeting HER2 and CD3 is developed for the treatment of HER2+ solid tumors, including breast and gastric cancers; and ABP-201, a TetraBi antibody format that simultaneously inhibit VEGF and ANG-2 for the treatment of vascular diseases of the eye, including diabetic macular edema and wet age-related macular degeneration. It also develops ABP-110, a TetraBi antibody targeting GPC3 and CD3 for the treatment of hepatocellular carcinoma; and ABP-150, a TetraBi antibody targeting claudin 18.2 and CD3 for the treatment of gastric cancers. The company has strategic partnership with Celltrion Inc. and Abpro Bio International, Inc. Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Woburn, Massachusetts.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap